A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

Novartis

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: valsartan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00171353

CVAL489ARU01

Details and patient eligibility

About

One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.

Enrollment: 109 patients

Sex: All

Ages: 30 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Arterial hypertension without previous regular treatment
• Urinary albumin excretion rate above 30 mg / 24h
• 30-65 years old

Exclusion criteria

• Reno-vascular arterial hypertension
• Therapy resistant edema
• Chronic heart failure, angina pectoris
• Diabetes mellitus

Other protocol-defined exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)